source
- GSK drops camlipant cough drug after mixed Phase 3 resultsGSK announced it is halting development of camlipant, an experimental chronic cough medicine it acquired in a $2 billion purchase three years ago. The decision follows two Phase 3 trials that show…
- Jasper Therapeutics secures $132 million and merges with Kira Pharmaceuticals to revive pipelineJasper Therapeutics, a cash‑strapped biotech, announced it completed an all‑stock acquisition of privately held immune‑drug developer Kira Pharmaceuticals. The merger is paired with a private stoc…